NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Nov 18 2021

· Issued by NATCO Pharma Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

NATCO Pharma Limited has issued a press release announcing the launch of Tipanat tablets in India for treating advanced colorectal and gastric cancer. Tipanat is a fixed-dose combination of Trifluridine and Tipiracil, marking its first introduction in the Indian market. The company emphasizes the importance of Tipanat in extending survival and improving quality of life for patients with these cancers.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Natco Pharma Limited has informed the Exchange regarding a press release dated November 18, 2021, titled "NATCO launches Tipanat tablets in India, for the treatment of advancedcolorectal and gastric cancer".

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases